The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Morl Christopher John since 2019.
The trader's CIK number is 1716821.
At the time of the last reporting, Morl Christopher John was the Chief Business Officer of Deciphera Pharmaceuticals, Inc.. (stock ticker symbol DCPH).
Also see all insider trading activities at Deciphera Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | DCPH | 0 | $0 | 45,102 | $2,786,779 | 45,102 | $178,150 |
| 2019 | DCPH | 0 | $0 | 45,102 | $2,480,670 | 45,102 | $118,767 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-01-16 | DCPH | Option Ex | 3,011 | 3.95 | 11,893 |
| 2020-01-15 | DCPH | Sale | 12,023 | 65.23 | 784,272 |
| 2020-01-16 | DCPH | Sale | 3,011 | 65.40 | 196,931 |
| 2020-01-15 | DCPH | Option Ex | 12,023 | 3.95 | 47,490 |
| 2020-01-07 | DCPH | Option Ex | 1,650 | 3.95 | 6,517 |
| 2020-01-08 | DCPH | Option Ex | 12,281 | 3.95 | 48,509 |
| 2020-01-07 | DCPH | Sale | 1,650 | 60.02 | 99,036 |
| 2020-01-08 | DCPH | Sale | 12,281 | 60.12 | 738,272 |
| 2020-01-02 | DCPH | Sale | 16,137 | 60.00 | 968,268 |
| 2020-01-02 | DCPH | Option Ex | 16,137 | 3.95 | 63,741 |
| 2019-12-12 | DCPH | Option Ex | 15,034 | 3.95 | 59,384 |
| 2019-12-12 | DCPH | Sale | 15,034 | 60.00 | 902,040 |
| 2019-12-09 | DCPH | Sale | 3,387 | 55.00 | 186,285 |
| 2019-12-10 | DCPH | Sale | 11,647 | 55.00 | 640,585 |
| 2019-12-09 | DCPH | Option Ex | 3,387 | 3.95 | 13,378 |
| 2019-12-10 | DCPH | Option Ex | 11,647 | 3.95 | 46,005 |
| 2019-12-03 | DCPH | Option Ex | 15,034 | .00 | 0 |
| 2019-12-03 | DCPH | Sale | 15,034 | 50.00 | 751,760 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Morl Christopher John (Chief Business Officer of Deciphera Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.